Live immunogenic melanoma cells generated by etoposide treatment upregulate B2M and lose tumor-forming potential
Benjamin W. Lyon, Emma Russo, Cheyenne Colbert, Silas Vega, Tiffany Rose Emmons, Yi Wen Kong, Annabelle Sanders, Jani Benoit, Hilary M. Gaudet, Michael B. Yaffe, Ganapathy Sriram
This study shows that etoposide-treated B16-Ova melanoma cells upregulate B2M and lose tumor-forming potential while remaining viable and stimulating T-cell activation.
bioRxiv · Oct 20, 2026 · PreprintCancer Biology